AstraZeneca has entered an AI drug discovery partnership with biotech company insitro, in a deal valued at up to $1.86 billion. Techub, citing Crypto Briefing, reported that the agreement is aimed at using artificial intelligence to speed up the drug discovery process. The partnership brings together a major pharmaceutical company and an AI-focused biotech firm at a time when the use of machine learning in life sciences continues to draw attention. The report also said the collaboration could reshape industry dynamics, though no additional terms were disclosed in the source summary. The announcement centers on the size of the deal, the companies involved, and the role AI is expected to play in accelerating early-stage drug development.
AstraZeneca has struck an AI drug discovery pact with biotech firm insitro, and the deal can be worth up to $1.86 billion in total.
According to Crypto Briefing, cited by Techub, the tie-up is meant to use AI to speed up drug discovery and could reshape how the industry works.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.